EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression

Tomoya Yamashita, Haruki Horiguchi iD, Tsuyoshi Kadomatsu, Michio Sato, Toshiro Moroishi, Yuichi Oike

Genes to Cells · 2024

DOI: 10.1111/gtc.13177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes to Cells, 2024. Verfasst von Tomoya Yamashita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Immunotherapy, Mice, Inbred C57BL. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Takeda Science Foundation, Center for Metabolic Regulation of Healthy Aging (CMHA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic; however, ICI initiation can also cause an unexpectedly rapid acceleration of cancer progression in some patients. Here, we used a murine syngeneic melanoma model to conduct mechanistic analysis of cancer‐associated fibroblast (CAF) function in cancer progression in the context of immunotherapy. We found that after ICI treatment CAFs acquire inflammatory properties, which can promote tumor progression. Mechanistically, we show that T‐cell‐derived interferon‐γ (IFN‐γ) stimulates production of tumor necrosis factor‐α (TNF‐α) by macrophages, facilitating CAF conversion to inflammatory CAFs. Our findings suggest that CAF/immune cell crosstalk plays an essential role in ICI‐associated tumor progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsImmunotherapyMice, Inbred C57BLAnimalsMiceCellular ReprogrammingImmune Checkpoint InhibitorsInterferon-gammaMacrophagesDisease ProgressionTumor Necrosis Factor-alphaCell Line, TumorMelanoma, ExperimentalTumor MicroenvironmentT-LymphocytesHumans

Stichwörter der Autor:innen

cancer immunotherapy

Substanzen

Immune Checkpoint InhibitorsInterferon-gammaTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Pre-Shibasaburo Program, Kumamoto University, Kumamoto, Japan.
  • Department of Aging and Geriatric Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Haruki Horiguchi

Förderung

  • Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT)
  • Takeda Science Foundation
  • Center for Metabolic Regulation of Healthy Aging (CMHA)
  • Canadian Mental Health Association

Zitieren

APA

Yamashita, T., Horiguchi, H., Kadomatsu, T., Sato, M., Moroishi, T., & Oike, Y. (2024). Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression. Genes to Cells. https://doi.org/10.1111/gtc.13177

Vancouver

Yamashita T, Horiguchi H, Kadomatsu T, Sato M, Moroishi T, Oike Y. Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression. Genes to Cells. 2024. doi:10.1111/gtc.13177

BibTeX
@article{Yamashita2024,
  author = {Yamashita, Tomoya and Horiguchi, Haruki and Kadomatsu, Tsuyoshi and Sato, Michio and Moroishi, Toshiro and Oike, Yuichi},
  title = {Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression},
  journal = {Genes to Cells},
  year = {2024},
  doi = {10.1111/gtc.13177}
}
Kostenlos starten →